Molecular_JJ feature_NN mining_NN in_IN HIV_NN data_NNS
We_PRP present_VBP the_DT application_NN of_IN Feature_NNP Mining_NNP techniques_NNS to_TO the_DT Developmental_NNP Therapeutics_NNPS Program_NNP 's_POS AIDS_NNP antiviral_JJ screen_NN database_NN ._.
The_DT database_NN consists_VBZ of_IN 43576_CD compounds_NNS ,_, which_WDT were_VBD measured_VBN for_IN their_PRP$ capability_NN to_TO protect_VB human_JJ cells_NNS from_IN HIV-1_NN infection_NN ._.
According_VBG to_TO these_DT measurements_NNS ,_, the_DT compounds_NNS were_VBD classified_VBN as_IN either_CC active_JJ ,_, moderately_RB active_JJ or_CC inactive_JJ ._.
The_DT distribution_NN of_IN classes_NNS is_VBZ extremely_RB skewed_JJ :_: Only_RB 1.3_CD %_NN of_IN the_DT molecules_NNS is_VBZ known_VBN to_TO be_VB active_JJ ,_, and_CC 2.7_CD %_NN is_VBZ known_VBN to_TO be_VB moderately_RB active_JJ ._.
Given_VBN this_DT database_NN ,_, we_PRP were_VBD interested_JJ in_IN molecular_JJ substructures_NNS -LRB-_-LRB- i.e._FW ,_, features_NNS -RRB-_-RRB- that_WDT are_VBP frequent_JJ in_IN the_DT active_JJ molecules_NNS ,_, and_CC infrequent_JJ in_IN the_DT inactives_NNS ._.
In_IN data_NN mining_NN terms_NNS ,_, we_PRP focused_VBD on_IN features_NNS with_IN a_DT minimum_JJ support_NN in_IN active_JJ compounds_NNS and_CC a_DT maximum_JJ support_NN in_IN inactive_JJ compounds_NNS ._.
We_PRP analyzed_VBD the_DT database_NN using_VBG the_DT levelwise_JJ version_NN space_NN algorithm_NN that_WDT forms_VBZ the_DT basis_NN of_IN the_DT inductive_JJ query_NN and_CC database_NN system_NN MOLFEA_NN -LRB-_-LRB- Molecular_JJ Feature_NNP Miner_NNP -RRB-_-RRB- ._.
Within_IN this_DT framework_NN ,_, it_PRP is_VBZ possible_JJ to_TO declaratively_RB specify_VB the_DT features_NNS of_IN interest_NN ,_, such_JJ as_IN the_DT frequency_NN of_IN features_NNS on_IN -LRB-_-LRB- possibly_RB different_JJ -RRB-_-RRB- datasets_NNS as_RB well_RB as_IN on_IN the_DT generality_NN and_CC syntax_NN of_IN them_PRP ._.
Assuming_VBG that_IN the_DT detected_VBN substructures_NNS are_VBP causally_RB related_JJ to_TO biochemical_JJ mechanisms_NNS ,_, it_PRP should_MD be_VB possible_JJ to_TO facilitate_VB the_DT development_NN of_IN new_JJ pharmaceuticals_NNS with_IN improved_JJ activities_NNS ._.
